Foresite Capital Management Iv, LLC Lyell Immunopharma, Inc. Transaction History
Foresite Capital Management Iv, LLC
- $87.8 Million
- Q1 2025
A detailed history of Foresite Capital Management Iv, LLC transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Foresite Capital Management Iv, LLC holds 16,007,999 shares of LYEL stock, worth $144 Million. This represents 9.84% of its overall portfolio holdings.
Number of Shares
16,007,999
Previous 8,325,000
92.29%
Holding current value
$144 Million
Previous $5.33 Million
62.24%
% of portfolio
9.84%
Previous 4.9%
Shares
6 transactions
Others Institutions Holding LYEL
# of Institutions
117Shares Held
175MCall Options Held
2.9KPut Options Held
6K-
Mwg Management Ltd. Washington, DC20.2MShares$181 Million18.54% of portfolio
-
Apoletto LTD Washington, DC15.1MShares$136 Million42.56% of portfolio
-
Orland Properties LTD Washington, DC15.1MShares$136 Million9.84% of portfolio
-
Black Rock Inc. New York, NY13.5MShares$121 Million0.0% of portfolio
-
Decheng Capital LLC Menlo Park, CA11.9MShares$107 Million1.8% of portfolio
About Lyell Immunopharma, Inc.
- Ticker LYEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 247,824,992
- Market Cap $2.23B
- Description
- Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...